To address the issue of regulatory process of biosimilars, including intended copies*, the Americas Health Foundation (AHF) conducted a literature review and convened a panel with eight experts in biological cancer therapies and health economics to address the most salient issues concerning the regulation of biosimilars in Latin America .
Biosimilar regulations perspective in Latin America to improve cancer treatment access
Biosimilars/Research | Posted 22/07/2022 0 Post your comment
The development of biological and biotechnological products in Latin America is remarkably diverse due to the particularities related to numerous factors such as cultural, economic, political, and regulatory factors. Each Latin American country therefore has a unique market and regulatory outlook . Given this scenario, a revision of their regulatory pathways was considered.
This policy review conducted by AHF with eight-member expert panel from Colombia, Chile, Ecuador, Guatemala and Peru, was focused in five Latin American countries.
The regulatory challenges identified by the panel members included heterogenous regulations, non-adherence to regulatory pathways, scarcity of market opportunity, inadequate naming of biosimilars by only using international non-proprietary names,
imprecise use of interchangeability and substitution, and insufficient traceability and pharmacovigilance.
The panel members developed recommendations to improve the implementation of biosimilar regulatory pathways and consistent procurement strategies to increase their access to patients mainly with breast cancer and colorectal cancer, which are the second and third most common cancers in Latin America.
Biologicals have become an integral part of breast cancer care with the arrival of trastuzumab, Similarly, biologicals are often used in advanced treatment of colorectal cancer, including antiangiogenic agents such as bevacizumab, aflibercept and ramucirumab. But perhaps the main barrier to easily getting a patient on a biological remains in their high cost and limited availability, thus biosimilars are an effective and equivalent alternative to originator biologicals, which contribute to the sustainability and financing of healthcare systems and favour access to biological therapies with the same safety, efficacy and quality as the original product.
The recommendations given in the policy review are not intended as a unified solution for the Latin American region and should be tailored on a country-by-country basis and can serve as a strategy for biosimilar adoption in other countries in a similar situation .
*Intended copies (also known as non-comparables, biocopies, biomimics, and non-regulated biosimilars) are copies of originators that have not undergone the stringent regulatory process for biosimilars. They are copies of already licensed biological products that have not met the requirements of the WHO, EMA, or FDA to establish biosimilarity .
GaBI Journal Citation Impact
2.2 – CiteScore 2021 (calculated on 5 May 2022)
2.3 – CiteScoreTracker 2022 (Last updated on 6 July 2022)
Submit a manuscript to GaBI Journal
Access to biosimilars for cancer treatments in Latin America
Current status of monoclonal antibody biosimilars approved in Latin America
Overview of monoclonal antibody biosimilars in Latin America
Regulatory landscape for similar biotherapeutic products in Latin America
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.
View this week’s headline article: Perspectiva de la regulación de biosimilares en América Latina para mejorar el acceso al tratamiento del cáncer
Browse the news in the Latin American Forum!
Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.
Vea el artículo principal de esta semana: Perspectiva de la regulación de biosimilares en América Latina para mejorar el acceso al tratamiento del cáncer
!Explore las noticias en el Foro Latinoamericano!
Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
1.Teran E, Gomez H, Hannois D, Lema M, Mantilla W, Rico-Restrepo M, McElwee E, Castro Sanchez N, Valdivieso N, Espinoza MA. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. Lancet Oncol. 2022 Jul;23(7):e348-e358. doi: 10.1016/S1470-2045(22)00121-8. PMID: 35772466.
2. GaBI Online - Generics and Biosimilars Initiative. Regulation of the registration of biological drugs in Latin America [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jul 22]. Available from: www.gabionline.net/biosimilars/research/regulation-of-the-registration-of-biological-drugs-in-latin-america
3. GaBI Online - Generics and Biosimilars Initiative. Glosario de términos principales [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jul 22]. Available from: www.gabionline.net/biosimilars/general/glosario-de-terminos-principales
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
Post your comment
New indication for Cosentyx (secukinumab) biological: hidradenitis suppurativa
Advances for STADA-Xbrane’s Ximluci in Europe, the UK and the US
An update on the joint EMA-HMA statement on interchangeability of biosimilar
Biosimilars switching policies for Canada’s Newfoundland and Labrador, and Yukon
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
High mannose glycans in biosimilars and their pharmacokinetic impact
Biosimilars in Southern European Hospital Markets: barriers and determinants of uptake
Using infliximab economic evaluations in IBD to inform biosimilar access policies
Post your comment